You draw your dose with a syringe, allowing precise microdosing and reducing waste
Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo Primary Outcome Measure: Relative change in body weight Time Frame: From baseline (week 0) to week 80 Study Details Source VK2735 for Weight Management Phase 3 (VANQUISH 1) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes
Compared to individuals with obesity of other etiologies matched for BMI (body mass index), they have lower levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides
Consume within 24 hours
10.1074/jbc.M110.142315 48 KokavecA
Herman GA, Stein PP, Thornberry NA, Wagner JA
